Table 5.
Base Case and Plausible Ranges of Model Cost
| Parameter | Base case | Upper limit | Lower limit | Resource |
|---|---|---|---|---|
| Direct medical costs | ||||
| Drug costs (EG) | 1,310.49 | 1,441.54 | 1,179.44 | GISAA |
| Drug costs (CG) | 59.20 | 65.12 | 53.28 | GISAA |
| Examination costs | 1,634.70 | 1,798.17 | 1,471.23 | China Health Statistics Yearbook |
| Bed costs | 515.00 | 566.50 | 463.50 | China Health Statistics Yearbook |
| Other treatment costs (EG) | 12,265.00 | 13,491.5 | 11,038.5 | GISAA |
| Other treatment costs (CG) | 10,102.00 | 11,112.2 | 9,091.8 | GISAA |
| Direct nonmedical costs | ||||
| Care costs (EG) | 1,228.57 | 1351.424 | 1,105.71 | GISAA |
| Care costs (CG) | 1,226.58 | 1349.2396 | 1,103.92 | GISAA |
| Transportation costs (EG) | 1,140.50 | 1,235.30 | 1,045.80 | GISAA |
| Transportation costs (CG) | 1,198.80 | 1,303.70 | 1,093.80 | GISAA |
| Nursing costs (after discharge) | ||||
| mRS 0–2 | 8,316.20 | 9,147.815 | 7,484.58 | Pan et al.23 |
| mRS 3–5 | 12,781.15 | 14,059.27 | 11,503.04 | Pan et al.23 |
| Recurrent treatment costs | 28,987.05 | 31,885.76 | 26,088.35 | Pan et al.,23 Wang et al.24 |
CG, control group; EG, experiment group; GISAA, Ginkgolide in Ischemic Stroke Patients with Large Artery Atherosclerosis; mRS, modified Rankin Scale.